Umbilical Cord News and Research

RSS
The umbilical cord is the structure that attaches the fetus to the placenta and acts as the medium through which nutrients, gases and waste products travel between the mother and the fetus.
Androgen replacement therapy may ward off heart damage, says study

Androgen replacement therapy may ward off heart damage, says study

Jiangsu Government grants $1.8M for research and development of hUC-MSC technologies

Jiangsu Government grants $1.8M for research and development of hUC-MSC technologies

Cord Blood America signs Letter of Intent to process and store cord blood specimens for BioCells

Cord Blood America signs Letter of Intent to process and store cord blood specimens for BioCells

Umbilical cord stem cells may be useful in treating blood disorders

Umbilical cord stem cells may be useful in treating blood disorders

Breast Cancer Fund: It's time for the FDA to issue immediate ban on BPA in hard plastic food containers

Breast Cancer Fund: It's time for the FDA to issue immediate ban on BPA in hard plastic food containers

Financial results for second fiscal quarter announced by China Cord Blood

Financial results for second fiscal quarter announced by China Cord Blood

New findings may help restore vision in patients with corneal injury

New findings may help restore vision in patients with corneal injury

Breast Cancer Fund: Congress must enforce BPA ban in food and beverage containers

Breast Cancer Fund: Congress must enforce BPA ban in food and beverage containers

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

Cord Blood reports its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009

Cord Blood reports its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics announces the completion of $30 million Series B financing

Two units of UCB reduce risk of leukemia from returning, shows new study

Two units of UCB reduce risk of leukemia from returning, shows new study

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

Cord Blood America answers shareholder questions about its new laboratory in Las Vegas

Cord Blood America answers shareholder questions about its new laboratory in Las Vegas

Hard to Treat Diseases negotiating possible merger with EU based stem cell research company

Hard to Treat Diseases negotiating possible merger with EU based stem cell research company

Study links urogenital birth defects with DDT

Study links urogenital birth defects with DDT

DDT exposure is associated with urogenital birth defects in newborn boys

DDT exposure is associated with urogenital birth defects in newborn boys

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

NCCN Guidelines for Acute Myeloid Leukemia updated

NCCN Guidelines for Acute Myeloid Leukemia updated

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.